The Development of Peptide Vaccines for Triple Negative Breast Cancer Treatment
Project/Area Number |
26461965
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Kurume University |
Principal Investigator |
Toh Uhi 久留米大学, 医学部, 准教授 (60268901)
|
Co-Investigator(Renkei-kenkyūsha) |
ITOH Kyogo 久留米大学, 医学部, 教授 (50125499)
SHICHIJO Shigeki 久留米大学, 医学部, 准教授 (30080592)
YAMADA Akira 久留米大学, 医学部, 教授 (50158177)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | ペプチドワクチン / トリプルネガティブ乳癌 / 乳がん / トリプルネガティブ乳がん |
Outline of Final Research Achievements |
We conducted an early phase II study to evaluate the safety and the efficacy of a new regimen using multiple peptide vaccines (KRM-19) for patients (pts) with metastatic triple negative breast cancer (mTNBC). KRM-19 consisted of 19 mixed peptides were chosen from the previously reported 31 peptide vaccines according to their immunologic effect and safety profile. All pts had histologically confirmed measurable ER-PgR-Her2- mBC. KRM-19 was administrated subcutaneously every week for 6 doses. The chemo-endocrine therapy were not permitted for the combination. The primary endpoint was safety and anti-tumor immunologic effect, and the secondary endpoints were clinical responses and progression free survival (PFS). 11 pts have been enrolled. Measurement of peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were conducted before and after vaccination. Correlation between PFS and the increased IgG response and/or CTL levels will be investigated. (Registry number: UMIN000014616)
|
Academic Significance and Societal Importance of the Research Achievements |
近年乳がんの治療成績が飛躍的に向上されたが、トリプルネガティブ(ER陰性、PgR陰性、HER2陰性)乳がんは依然治療手段が限られている。様々な抗がん剤や分子標的治療薬が臨床治療に実用されるようになっているが、副作用の少ないがんワクチンが開発された場合は大きな意義を有する。今回、HLA型に関わらず投与可能な19種類ペプチドカクテル(KRM-19)を開発し、その臨床投与により安全性と有効性を検証するとともに、乳癌癌局所の組織免疫環境やこれまでワクチン療法を受けた患者の血液サンプルの抗体化などの変化を解析し、臨床的にワクチン療法で有効な患者群を検証し、新しい乳癌の集学的治療法が確立に繋がる。
|
Report
(4 results)
Research Products
(90 results)
-
[Journal Article] Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.2017
Author(s)
Okabe M, Toh U, Iwakuma N, Saku S, Akashi M, Kimitsuki Y, Seki N, Kawahara A, Ogo E, Itoh K, Akagi Y.
-
Journal Title
Cancer Sci.
Volume: 108
Issue: 1
Pages: 81-90
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.2017
Author(s)
Shibata T, Watari K, Izumi H, Kawahara A, Hattori S, Fukumitsu C, Murakami Y, Takahashi R, Toh U, Ito KI, Ohdo S, Tanaka M, Kage M, Kuwano M, Ono M.
-
Journal Title
Cancer Res.
Volume: 77(2)
Pages: 545-556
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.2015
Author(s)
Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K.
-
Journal Title
Cancer Sci.
Volume: 106
Issue: 10
Pages: 1257-1263
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes.2014
Author(s)
Oba MS, Imoto S, Toh U, Wada N, Kawada M, Kitada M, Masuda N, Taguchi T, Minami S, Jinno H, Sakamoto J, Morita S; Japanese Society for Sentinel Node Navigation Surgery.
-
Journal Title
Jpn J Clin Oncol.
Volume: 44
Issue: 9
Pages: 876-879
DOI
Related Report
Peer Reviewed
-
[Journal Article] Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.2014
Author(s)
Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M, Fujii T, Seki N, Kawahara A, Kage M, Matsueda S, Akagi Y, Yamada A, Itoh K, Sasada T.
-
Journal Title
Breast Cancer Res.
Volume: 16
Issue: 4
Pages: 00-00
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Moleculary-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER”-Targeted Therapy,mTOR Inhibitor and Antiangiogenic Therapy2014
Author(s)
Teruhiko Fujii,Keisuke Miwa,Tomoyuki Ushijima,Mototsugu Matsunaga,Masaru Fukahori,Kotaro Yuge,Uhi Toh,Nobutaka Iwakuma,Ryuji Takahashi,Hiroki Takahashi,Miki Takenaka,Mai Mishima,Yoshito Akagi,Masayoshi Kage,Shino Nakagawa,Maki Tanaka
-
Journal Title
Frontiers in Anti-Cancer Drug Discovery
Volume: 4
Pages: 157-228
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Correlation between HER2 related biomarkers (HER2, p95HER2, HER3, PTEN and PIK3CA) and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer refractory to trastuzumab2016
Author(s)
Reiki Nishimura, Uhi Toh, Maki Tanaka, Michiyo Saimura, Yasuhiro Okumura, Tsuyoshi Saito, Toshihiro Tanaka, Megumi Teraoka, Kazuo Shimada, Kazuhisa Katayama, Toshihiro Koga, Kaname Kurashita, Satoshi Hasegawa, Hidekazu Todoroki, Hiroaki Ueo, Nobuyuki Arima, Shoshu Mitsuyama, Kazuo Tamura
Organizer
2016 ASCO Annual Meeting
Place of Presentation
シカゴ
Year and Date
2016-06-03
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for berast cancer patients in the adjuvant setting.2014
Author(s)
U.Toh,N.Iwakuma,M.Mishima,M.Takenaka,R.Takahashi,M.Furukawa,T.Fujii,E.Ogo,S.Nakagawa,M.Tanaka,T.Sasada,K.Itoh,Y.Akagi
Organizer
2014 ASCO Annual Meeting
Place of Presentation
Chicago, USA
Year and Date
2014-05-30 – 2014-06-03
Related Report
-
-
-
-
-
-
-
-
-
-
-